Literature DB >> 29718244

Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey.

Aaron Yarlas1, David T Rubin2, Julian Panés3, James O Lindsay4, Séverine Vermeire5, Martha Bayliss1, Joseph C Cappelleri6, Stephen Maher1, Andrew G Bushmakin6, Lea Ann Chen7, Marco DiBonaventura8.   

Abstract

BACKGROUND AND AIMS: This review is the first to evaluate the burden of ulcerative colitis [UC] on patients' quality of life by synthesizing data from studies comparing scores from the SF-36® Health Survey, a generic measure assessing eight quality-of-life domains, between UC patients and matched reference samples.
METHODS: A systematic review of the published literature identified articles reporting SF-36 domains or physical and mental component summary scores [PCS, MCS] from UC and reference samples. Burden of disease for each SF-36 domain was then summarized across studies by comparing weighted mean differences in scores between patient and reference samples with minimally important difference thresholds.
RESULTS: Thirty articles met pre-specified inclusion criteria. SF-36 scores were extracted from five samples of patients with active disease, 11 samples with a mixture of disease activity, five samples of patients in clinical remission, and 13 samples of patients following proctocolectomy with ileostomy or ileal pouch-anal anastomosis, along with respective reference samples. Clinically meaningful burden was observed in samples with active or mixed disease activity [deficits: PCS = 5.6, MCS = 5.5] on all SF-36 domains except Physical Functioning. No burden was observed in samples in remission or post-surgical patients [deficits: PCS = 0.8, MCS = 0.4] except for the General Health perception domain.
CONCLUSIONS: Patients with active UC experience a clinically meaningful burden of disease across most aspects of quality of life. Patients with inactive UC exhibit negligible disease burden and are comparable to the general population on most quality-of-life outcomes. Thus, treatments which effectively induce and maintain remission may restore physical and mental health status.

Entities:  

Mesh:

Year:  2018        PMID: 29718244     DOI: 10.1093/ecco-jcc/jjy024

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  14 in total

1.  The ulcerative colitis narrative Greece survey: patients' and physicians' perspective on quality of life and disease management.

Authors:  Nikos Viazis; Anastasia Stefanidou; Gerasimos J Mantzaris
Journal:  Ann Gastroenterol       Date:  2022-03-25

2.  The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Authors:  Aaron Yarlas; Mary Kaye Willian; Arpita Nag
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

3.  Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.

Authors:  Hamed Khalili; Åsa H Everhov; Jonas Halfvarson; Jonas F Ludvigsson; Johan Askling; Pär Myrelid; Jonas Söderling; Ola Olen; Martin Neovius
Journal:  Aliment Pharmacol Ther       Date:  2020-07-03       Impact factor: 9.524

4.  Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea.

Authors:  Jung Rock Moon; Chang Kyun Lee; Sung Noh Hong; Jong Pil Im; Byong Duk Ye; Jae Myung Cha; Sung-Ae Jung; Kang-Moon Lee; Dong Il Park; Yoon Tae Jeen; Young Sook Park; Jae Hee Cheon; Hyesung Kim; BoJeong Seo; Youngdoe Kim; Hyo Jong Kim
Journal:  Gut Liver       Date:  2020-07-15       Impact factor: 4.519

5.  Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation.

Authors:  Christoph Lohan; Alex Diamantopoulos; Corinne LeReun; Emily Wright; Natalie Bohm; Laura Marie Sawyer
Journal:  BMJ Open Gastroenterol       Date:  2019-07-30

6.  Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.

Authors:  Luciane de Fátima Caldeira; Helena H Borba; Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

7.  Health-related quality of life in patients with long-standing ulcerative colitis in remission.

Authors:  Georgios Mavroudis; Magnus Simrén; Lena Öhman; Hans Strid
Journal:  Therap Adv Gastroenterol       Date:  2022-02-11       Impact factor: 4.409

8.  Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country.

Authors:  Edward Mezones-Holguin; Rocio Violeta Gamboa-Cardenas; Gadwyn Sanchez-Felix; José Chávez-Corrales; Luis Miguel Helguero-Santin; Luis Max Laban Seminario; Paula Alejandra Burela-Prado; Maribel Marilu Castro-Reyes; Fabian Fiestas
Journal:  Front Pharmacol       Date:  2019-11-15       Impact factor: 5.810

9.  The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.

Authors:  Alessandro Armuzzi; Miriam Tarallo; James Lucas; Daniel Bluff; Benjamin Hoskin; Danielle Bargo; Joseph C Cappelleri; Leonardo Salese; Marco daCosta DiBonaventura
Journal:  BMC Gastroenterol       Date:  2020-01-21       Impact factor: 3.067

10.  Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis.

Authors:  Matthew J Brookes; John Waller; Joseph C Cappelleri; Irene Modesto; Marco D DiBonaventura; Natalie Bohm; Ruth Mokgokong; Olivia Massey; Robert Wood; Danielle Bargo
Journal:  BMJ Open Gastroenterol       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.